摘要：作为肿瘤学领域的国际盛会，ASCO年会每年都吸引着来自世界各地的顶尖学者、临床专家与科研团队，共同分享最新研究成果、探讨创新疗法、展望未来趋势。随着2025年ASCO年会完整日程的正式公布，全球肿瘤学界的目光再次聚焦于此。在此，医脉通特整理了本届ASCO大会中

胃食管癌

Oral Abstract Session

报告时间：GMT-5 15:00-15:36（5月31日）；GMT+8 04:00-04:36（6月1日）

报告地点：Hall D1

摘要号：4003

研究名称（英文）：Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01).

研究名称（中文）：Claudin18.2特异性CAR T细胞（Satri-cel）对比医生选择的治疗方案应用于既往接受过治疗的晚期GC/GEJC患者：随机、开放标签、II期CT041-ST-01试验的主要结果。

讲者：齐长松 | 北京大学肿瘤医院

Rapid Oral Abstract Session

报告时间：GMT-5 11:30-12:06（6月2日）；GMT+8 00:30-01:06（6月3日）

报告地点：Hall D2

摘要号：LBA4012

研究名称（英文）：Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (C)/trastuzumab (Tra) as first-line (1L) treatment of patients (pts) with HER2-expressing locally advanced or metastatic (la/m) gastric cancer.

研究名称（中文）：维迪西妥单抗联合特瑞普利单抗和化疗/曲妥珠单抗作为局部晚期或转移性HER2表达胃癌患者的一线（1L）治疗。

讲者：沈琳 | 北京大学肿瘤医院

摘要号：4015

研究名称（英文）：Decoding the response and resistant features to the Claudin18.2-specific CAR-T cell CT041 in gastric cancer: A multi-omics exploratory biomarker analysis of the phase 1 clinical trial.

研究名称（中文）：揭秘胃癌中Claudin18.2特异性CAR-T细胞CT041的应答和耐药性特征：I期临床试验的多组学探索性生物标志物分析。

讲者：彭昊昕 | 北京大学肿瘤医院

摘要号：4016

研究名称（英文）：Cosiporfin sodium (DVDMS)-mediated photodynamic therapy (PDT) versus treatment of physician's choice (TPC) in patients (pts) with advanced esophageal cancer (aEC): A phase III, randomized, open-label, multicenter trial.

研究名称（中文）：华卟啉钠介导的光动力疗法（PDT）对比医师选择治疗（TPC）治疗晚期食管癌患者：一项III期、随机、开放标签、多中心试验。

讲者：周军 | 北京大学肿瘤医院

Poster Session

摘要号：4025 | 壁报编号：315

研究名称（英文）：HER2 expression dynamics and prognostic significance in the treatment of gastric cancer.

讲者：Min Lai | 南方医科大学南方医院

摘要号：4027 | 壁报编号：317

研究名称（英文）：Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)–guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis.

讲者：陈龙奇 | 四川大学华西医院

摘要号：4028 | 壁报编号：318

研究名称（英文）：Efficacy and safety of surufatinib (Sur) plus paclitaxel (Pac) as second line (2L) treatment for advanced gastric cancer (aGC): Final results from a phase 2 trial.

讲者：肖秀英 | 上海交通大学医学院附属仁济医院

摘要号：4031 | 壁报编号：321

研究名称（英文）：Safety, efficacy, and biomarker analysis from a phase II trial of intensive chemotherapy combined with serplulimab and trastuzumab in patients with advanced HER2-positive gastric cancer.

讲者：刘天舒 | 复旦大学附属肿瘤医院

摘要号：4032 | 壁报编号：322

研究名称（英文）：Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)–guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis.

讲者：龚继芳 | 北京大学肿瘤医院

摘要号：4038 | 壁报编号：328

研究名称（英文）：Efficacy and safety results of a multi-center phase II study of utidelone injection in combination with PD-1 inhibitor and chemotherapy for the first-line treatment of advanced gastric and esophagus cancers.

讲者：侯新芳 | 河南省肿瘤医院

摘要号：4040 | 壁报编号：330

研究名称（英文）：HER2 expression dynamics and prognostic significance in the treatment of gastric cancer.

讲者：孙美丽 | 山东第一医科大学附属中心医院

摘要号：4042 | 壁报编号：332

研究名称（英文）：Fruquintinib in combination with camrelizumab and paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II study.

讲者：Yanhong Gu | 南京医科大学第一附属医院

摘要号：4044 | 壁报编号：334

研究名称（英文）：Second-line ASKB589 plus chemotherapy for advanced gastric or gastroesophageal cancers: Results from cohort 5 of a phase I/II study.

讲者：龚继芳 | 北京大学肿瘤医院

摘要号：4046 | 壁报编号：336

研究名称（英文）：Updated results of fruquintinib combined with PD-1 inhibitors and chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma (FDZL-FIX): A single-arm, open-label phase 2 study.

讲者：王辰辰 | 复旦大学附属肿瘤医院

摘要号：4050 | 壁报编号：340

研究名称（英文）：Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)–guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis.

讲者：沙丹 | 山东省立医院

摘要号：4052 | 壁报编号：342

研究名称（英文）：Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment of HER-2 negative unresectable locally advanced or advanced gastric and gastroesophageal junction adenocarcinoma: A phase II clinical trial.

讲者：陈椿 | 福建医科大学附属协和医院

摘要号：4053 | 壁报编号：343

研究名称（英文）：HER2 expression dynamics and prognostic significance in the treatment of gastric cancer.

讲者：qian zhao | 山东第一医科大学附属肿瘤医院

摘要号：4054 | 壁报编号：344

研究名称（英文）：Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)–guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis.

讲者：qian zhao | 山东第一医科大学附属肿瘤医院

摘要号：4057 | 壁报编号：347

研究名称（英文）：Efficacy and safety of surufatinib (Sur) plus paclitaxel (Pac) as second line (2L) treatment for advanced gastric cancer (aGC): Final results from a phase 2 trial.

讲者：Maohui Chen | 福建医科大学附属协和医院

摘要号：4059 | 壁报编号：349

研究名称（英文）：Disitamab vedotin (RC48), tislelizumab, and S-1 as first-line therapy for HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from the RCTS trial.

讲者：刘联 | 山东大学齐鲁医院

摘要号：4061 | 壁报编号：351

研究名称（英文）：Feasibility of circulating tumor DNA-based minimal residual disease (ctDNA-MRD)-guided adjuvant chemotherapy in patients with stage II-III gastric cancer (GC): An adaptive trial (MRD-GATE).

讲者：刘联 | 山东大学齐鲁医院

摘要号：4069 | 壁报编号：359

研究名称（英文）：Neoadjuvant toripalimab plus CapeOX in patients with locally advanced EBV-positive gastric or esophagogastric junction adenocarcinoma (GC/EGJC): Results from the phase II NICE trial.

讲者：赵丽瑛 | 南方医科大学南方医院

摘要号：4070 | 壁报编号：360

研究名称（英文）：Early detection and neoadjuvant efficacy prediction for esophageal cancer using cfDNA methylation-based liquid-biopsy assay.

讲者：李志刚 | 上海交通大学医学院附属胸科医院

摘要号：4074 | 壁报编号：364

研究名称（英文）：The lost evidence: A phase III, multicenter randomized controlled trial of neoadjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA–IIIB esophageal squamous cell carcinoma.

讲者：李印 | 中国医学科学院肿瘤医院

摘要号：4076 | 壁报编号：366

研究名称（英文）：An interim analysis of phase III study on neoadjuvant chemotherapy versus perioperative toripalimab plus neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909).

讲者：Yan Zheng | 河南省肿瘤医院

肝胆胰肿瘤

Rapid Oral Abstract Session

报告时间：GMT-5 12:12-12:30（6月2日）；GMT+8 01:12-01:30（6月3日）

报告地点：Hall D2

摘要号：4017

研究名称（英文）：Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): Results from a phase I dose expansion cohort evaluating IBI343.

研究名称（中文）：Claudin18.2在胰腺导管腺癌中的表达和疗效：来自评估IBI343的I期研究剂量扩展队列的结果。

讲者：虞先濬 | 复旦大学附属肿瘤医院

Clinical Science Symposium

报告时间：GMT-5 08:12-08:48（6月2日）；GMT+8 21:12-21:48（6月2日）

报告地点：Hall D2

摘要号：4010

研究名称（英文）：Efficacy and safety of cafelkibart (LM-108), an anti-CCR8 monoclonal antibody, in combination with anti-PD-1 therapy in patients with pancreatic cancer: Results from phase 1/2 studies.

研究名称（中文）：抗 CCR8 单克隆抗体 cafelkibart (LM-108) 与抗 PD-1 疗法联合治疗胰腺癌患者的疗效和安全性：I/II期研究结果。

讲者：龚继芳 | 北京大学肿瘤医院

Poster Session

摘要号：4080 | 壁报编号：370

研究名称（英文）：First-line rilvegostomig (rilve) plus chemotherapy (CTx) in advanced biliary tract cancer (BTC): Primary analysis of GEMINI-Hepatobiliary substudy 2 Cohort A.

讲者：周俭 | 复旦大学附属中山医院

摘要号：4084 | 壁报编号：374

研究名称（英文）：Phase I study of Ori-C101, an armored GPC3-directed CAR-T, in patients with advanced hepatocellular carcinoma (HCC).

讲者：Jieyi Shi | 复旦大学附属中山医院

摘要号：4087 | 壁报编号：377

研究名称（英文）：HAIC plus TAE combined with tislelizumab and surufatinib in unresectable intrahepatic cholangiocarcinoma: The REACH-01 trial.

讲者：Kangshuai Li | 山东大学齐鲁医院

摘要号：4088 | 壁报编号：378

研究名称（英文）：Efficacy and safety of regorafenib combination with PD-1 inhibitors vs. regorafenib monotherapy in second-line treatment for patients with unresectable hepatocellular carcinoma after failure of different first-line treatments: A multicenter retrospective real-world study.

讲者：Weihong Ma | 解放军总医院第五医学中心

摘要号：4090 | 壁报编号：380

研究名称（英文）：TACE-HAlC combined with donafenib and immune checkpoint inhibitors for BCLC stage C HCC patients (THEME study): A retrospective IPTW adjusted cohort study.

讲者：尹立楠 | 哈尔滨医科大学附属肿瘤医院

摘要号：4093 | 壁报编号：383

研究名称（英文）：SHR-8068 plus adebrelimab and bevacizumab for advanced hepatocellular carcinoma (aHCC): A phase 1b/2 study.

讲者：刘连新 | 中国科学技术大学附属第一医院

摘要号：4094 | 壁报编号：384

研究名称（英文）：Hepatic arterial infusion chemotherapy combined with donafenib and tislelizumab versus transcatheter chemoembolization alone for hepatocellular carcinoma: A propensity score matching study.

讲者：Tianqing Wu | 中山大学肿瘤防治中心

摘要号：4098 | 壁报编号：388

研究名称（英文）：A prospective, observational phase II clinical study evaluating hepatic artery infusion chemotherapy in combination with HLX10 and HLX04 as first-line treatment for patients with advanced hepatocellular carcinoma.

讲者：李慧锴 | 天津市肿瘤医院空港医院

摘要号：4100 | 壁报编号：390

研究名称（英文）：Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib plus transarterial chemoembolization in advanced hepatocellular carcinoma: An update on SHATA-001 study.

讲者：Zefeng Du | 中山大学肿瘤防治中心

摘要号：4104 | 壁报编号：394

研究名称（英文）：Radiomic analysis on pretreatment MRI to predict response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicenter study.

讲者：孙惠川 | 复旦大学附属中山医院

摘要号：4105 | 壁报编号：395

研究名称（英文）：Efficacy and safety of atezolizumab and bevacizumab with or without transarterial chemoembolization as first-line therapy for advanced hepatocellular carcinoma: An international multicenter real-world study.

讲者：张宁宁 | 天津市肿瘤医院

摘要号：4106 | 壁报编号：396

研究名称（英文）：Factors associated with immunotherapy response for hepatocellular carcinoma.

讲者：Shing Hin Chung | 香港大学

摘要号：4107 | 壁报编号：397

研究名称（英文）：Evolutionary divergence of the HLA-B genotype as a predictor of immune checkpoint inhibitor (ICI) therapy efficacy in hepatobiliary cancers.

讲者：张楠 | 北京协和医院

摘要号：4108 | 壁报编号：398

研究名称（英文）：Hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitors as first-line treatment for hepatocellular carcinoma with high tumor burden and portal vein tumor thrombus.

讲者：Jiaxi Liu | 中国医科大学附属第一医院

摘要号：4118 | 壁报编号：408

研究名称（英文）：Conversion therapy for initially unresectable intrahepatic cholangiocarcinoma: A multicenter real-world study.

讲者：Xinhao Xiong | 中山大学肿瘤防治中心

摘要号：4126 | 壁报编号：416

研究名称（英文）：Transarterial chemoembolization plus donafenib and immune checkpoint inhibitors for intermediate hepatocellular carcinoma (CHANCE2410): A propensity score matching analysis.

讲者：Bin-Yan Zhong | 浙江省肿瘤医院

摘要号：4127 | 壁报编号：417

研究名称（英文）：Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing immune checkpoint inhibitor and concurrent antiviral prophylaxis agents: A prospective observational study.

讲者：Zefeng Du | 中山大学肿瘤防治中心

摘要号：4128 | 壁报编号：418

研究名称（英文）：Comparative analysis of ctDNA-MRD and MVI in predicting postoperative recurrence of hepatocellular carcinoma.

讲者：Jianan Feng | 南方医科大学珠江医院

摘要号：4131 | 壁报编号：421

研究名称（英文）：Integration of cfDNA fragmentomics for early biliary tract cancer detection.

讲者：Jiwen Wang | 复旦大学附属中山医院

摘要号：4133 | 壁报编号：423

研究名称（英文）：Novel early-detection model based on cfDNA methylation and fragmentation features for liver cancer.

讲者：Xiaobo Wang | 广西医科大学附属肿瘤医院

摘要号：4134 | 壁报编号：424

研究名称（英文）：The efficacy and safety of donafenib as postoperative adjuvant therapy in patients at high risk of recurrence following radical resection of hepatocellular carcinoma (HCC): A multicenter retrospective study.

讲者：饶建华 | 江苏省人民医院

摘要号：4136 | 壁报编号：426

研究名称（英文）：Ultra-sensitive detection of hepatocellular carcinoma (HCC) with methylation signal enrichment of ctDNA and hepatitis B virus (HBV).Ultra-sensitive detection of hepatocellular carcinoma (HCC) with methylation signal enrichment of ctDNA and hepatitis B virus (HBV).

讲者：Nan Lin | 中山大学附属第三医院

摘要号：4139 | 壁报编号：429

研究名称（英文）：Neoadjuvant transhepatic arterial infusion chemotherapy (HAIC) with FOLFOX regime plus cadonilimab (PD-1/CTLA-4 bispecific antibody) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (CAR_Hero study).

讲者：Yongguang Wei | 广西医科大学第一附属医院

摘要号：4140 | 壁报编号：430

研究名称（英文）：Prognostic significance of pathological response in unresectable hepatocellular carcinoma treated with immune checkpoint inhibitor-based conversion therapy.

讲者：Wen-Jing Zheng | 复旦大学附属中山医院

摘要号：4141 | 壁报编号：431

研究名称（英文）：Comparison outcome of transarterial chemoembolization combined with immune checkpoint inhibitors plus bevacizumab or lenvatinib as first-line therapy for advanced hepatocellular carcinoma.

讲者：张宁宁 | 天津市肿瘤医院

摘要号：4144 | 壁报编号：434

研究名称（英文）：Impact of radionuclide therapy on survival outcomes for de novo metastatic gastroenteropancreatic neuroendocrine tumors: A population-based cohort study.

讲者：Zhiqiao Liu | 西南医科大学附属医院

摘要号：4157 | 壁报编号：447

研究名称（英文）：Efficacy and safety of surufatinib (S) plus KN046 (K) and chemotherapy in first line (1L) advanced pancreatic cancer (PC): A single-arm, phase 1b/2 trial.

讲者：王文权 | 复旦大学附属中山医院

摘要号：4159 | 壁报编号：449

研究名称（英文）：TQB2868 combined with anlotinib and nab-paclitaxel plus gemcitabine as first-line treatment for metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase 2 study.

讲者：Si Shi | 复旦大学附属肿瘤医院

摘要号：4160 | 壁报编号：450

研究名称（英文）：Phase II trial of serplulimab combined with gemcitabine plus nab-paclitaxel (GnP) and SBRT for metastatic pancreatic cancer as the first-line treatment.

讲者：成科 | 四川大学华西医院

摘要号：4161 | 壁报编号：451

研究名称（英文）：First-line treatment with surufatinib, camrelizumab, nab-paclitaxel, and S-1 in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): A phase Ib/II randomized study.

讲者：Guang-Hai Dai | 西南医科大学附属医院

摘要号：4162 | 壁报编号：452

研究名称（英文）：First-line serplulimab and bevacizumab combined with nab-paclitaxel/gemcitabine followed by mFOLFOX in advanced pancreatic cancer: A phase II trial.

讲者：应杰儿 | 复旦大学附属中山医院

摘要号：4165 | 壁报编号：455

研究名称（英文）：Homologous recombination deficiency (HRD) profiling in Chinese pancreatic ductal adenocarcinoma: Implications for platinum-based chemotherapy.

讲者：Yanxia Wang | 复旦大学附属肿瘤医院

摘要号：4174 | 壁报编号：464

研究名称（英文）：USP22 as promoter of Treg cell infiltration and modulator of immunotherapy efficacy through the PIAS1/P65/CCL22 pathway in pancreatic cancer.

讲者：Aman Wang | 四川大学华西医院

摘要号：4191 | 壁报编号：481

研究名称（英文）：Development and prospective validation of a novel cfDNA-based diagnostic model for the early detection of pancreatic cancer.

讲者：Xiuchao Wang | 天津市肿瘤医院

摘要号：4192 | 壁报编号：482

研究名称（英文）：Prognostic value of postoperative circulating tumor DNA and tumor markers in resected pancreatic adenocarcinoma (PAAD): An interim analysis of a prospective observational study.

讲者：Qian Zhan | 上海交通大学医学院附属瑞金医院

摘要号：4197 | 壁报编号：487

研究名称（英文）：Constructing genetic-immune prognostic subtypes of primary duodenal adenocarcinoma through whole exome sequencing and AI-assisted immune microenvironment analysis.

讲者：Ting Han | 上海交通大学医学院附属仁济医院

摘要号：TPS4201 | 壁报编号：491a

研究名称（英文）：Transarterial chemoembolization plus donafenib and immune checkpoint inhibitors for intermediate hepatocellular carcinoma (CHANCE2410): A propensity score matching analysis.

讲者：沈琳 | 北京大学肿瘤医院

摘要号：TPS4203 | 壁报编号：492a

研究名称（英文）：Open-label, single-arm, single-center phase 1b/2 clinical study of fruquintinib combined with trastuzumab and XELOX in the first-line treatment of advanced HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.

讲者：Huifang Lv | 郑州大学附属肿瘤医院

摘要号：TPS4204 | 壁报编号：492b

研究名称（英文）：ARTEMIDE-Gastric01: A phase 3 randomized study of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan (T-DXd) as first-line (1L) treatment for locally advanced or metastatic HER2-positive gastric or gastroesophageal junction cancer (GC/GEJC).

讲者：徐瑞华 | 中山大学肿瘤防治中心

摘要号：TPS4208 | 壁报编号：494b

研究名称（英文）：A phase II study of sacituzumab govitecan for advanced esophageal squamous cell carcinoma patients (SG-ESCC).

讲者：Tsung-Che Wu | 台湾大学医学院附设医院新竹分院

摘要号：TPS4213 | 壁报编号：497a

研究名称（英文）：Total neoadjuvant therapy with induction immunochemotherapy and chemoradiotherapy followed by surgery for locally advanced esophageal squamous cell carcinoma (TNT-ESCC).

讲者：Chien-Huai Chuang | 台湾大学医学院附设医院

摘要号：TPS4223 | 壁报编号：502a

研究名称（英文）：Donafenib combined with capecitabine for postoperative adjuvant therapy of biliary malignant tumors with high risk of recurrence: A multi-center, randomized controlled, phase II study.

讲者：饶建华 | 江苏省人民医院

结直肠癌

Oral Abstract Session

报告时间：GMT-5 14:45-17:09（5月30日）；GMT+8 03:45-06:09（5月31日）

报告地点：Arie Crown Theater

摘要号：LBA3502

研究名称（英文）：Anlotinib versus bevacizumab added to standard first-line chemotherapy among patients with RAS/BRAF wild-type, unresectable metastatic colorectal cancer: A multicenter, prospective, randomised, phase 3 clinical trial (ANCHOR trial).

研究名称（中文）：安罗替尼对比贝伐珠单抗联合一线标准化疗应用于RAS/BRAF野生型、不可切除的转移性结直肠癌：一项多中心、前瞻性、随机、III期临床试验（ANCHOR）。

讲者：丁克峰 | 浙江大学医学院附属第二医院

报告时间：GMT-5 11:30-12:42（6月1日）；GMT+8 00:30-01:42（6月2日）

报告地点：Hall D1

摘要号：LBA3516

研究名称（英文）：JMT101 in combination with irinotecan and SG001 versus regorafenib in patients with metastatic colorectal adenocarcinoma (mCRC): Results of a randomized, controlled, open-label, phase II study.

研究名称（中文）：JMT101联合伊立替康和SG001对比瑞戈非尼治疗转移性结直肠腺癌：一项随机、对照、开放标签、II期研究的结果。

讲者：许剑民 | 复旦大学附属中山医院

摘要号：3519

研究名称（英文）：Short-course radiotherapy followed by sintilimab and CAPOX as total neoadjuvant treatment in locally advanced rectal cancer: A prospective, randomized controlled trial (SPRING-01).

研究名称（中文）：短程放疗序贯信迪利单抗联合CAPOX作为局部晚期直肠癌患者的全程新辅助治疗：一项前瞻性、随机、对照试验（SPRING-01）。

讲者：靖昌庆 | 山东第一医科大学附属省立医院

报告时间：GMT-5 10:33（6月1日）；GMT+8 23:33（6月1日）

报告地点：Hall D1

摘要号：104

研究名称（英文）：Efficacy and safety of IBI363 monotherapy or in combination with bevacizumab in patients with advanced colorectal cancer

研究名称（中文）：IBI363单药治疗或联合贝伐单抗治疗晚期结直肠癌患者的疗效及安全性

讲者：林振宇 | 华中科技大学同济医学院附属协和医院

Poster Session

摘要号：3528 | 壁报编号：197

研究名称（英文）：Predictive role of circulating tumor DNA in pMMR locally advanced rectal cancer patients receiving neoadjuvant chemoradiotherapy combined with sintilimab.

讲者：Xiao-bin Zheng | 中山大学附属第六医院

摘要号：3532 | 壁报编号：201

研究名称（英文）：Predicting pathologic complete response in colorectal cancer patients after immunotherapy based on endoscopic biopsy and deep learning approach.

讲者：Chaoyuan Xiao | 四川大学华西医院

摘要号：3535 | 壁报编号：204

研究名称（英文）：COPEC trial: Early determination of pathological tumor response to neoadjuvant chemotherapy in low/intermediate risk stage II/II rectal cancer—A multicenter, non-inferiority phase III randomized trial.

讲者：mingtian wei | 四川大学华西医院

摘要号：3539 | 壁报编号：208

研究名称（英文）：Drug-eluting beads loaded with irinotecan-transarterial chemoembolization (DEBIRI-TACE) combined with hepatic artery infusion chemotherapy and regorafenib in colorectal liver metastases refractory to second-line and above standard systemic therapy: A single-center, phase II clinical trial (DREAM).

讲者：范文哲 | 中山大学附属第一医院

摘要号：3541 | 壁报编号：210

研究名称（英文）：Safety and efficacy of anti-CEA CAR-T cells to prolong relapse-free survival of colorectal cancer liver metastases patients after radical resection.

讲者：Wei Zhang | 上海长海医院

摘要号：LBA3555 | 壁报编号：224

研究名称（英文）：Safety and efficacy of reduced-port laparoscopic surgery for patients with colon and upper rectal cancer.

讲者：黄俊 | 中山大学附属第六医院

摘要号：3559 | 壁报编号：332

研究名称（英文）：The efficacy of watch and wait strategy or surgery after neoadjuvant immunotherapy for locally advanced colorectal cancer with dMMR/MSI-H guided by ctDNA dynamic monitoring (WINDOW): A single-center, open-label, prospective, phase II study.

讲者：Xuan Zhang | 云南省肿瘤医院

摘要号：3563 | 壁报编号：232

研究名称（英文）：A multicenter randomized phase II trial assessing the efficacy and safety of mCapOX plus cetuximab and mFOLFOX6 plus cetuximab as first-line treatment for patients with RAS/BRAF wild-type metastatic colorectal cancer: Primary results of the CAPCET study.

讲者：Yuwen Zhou | 四川大学华西医院

摘要号：3586 | 壁报编号：255

研究名称（英文）：Sintilimab plus bevacizumab, oxaliplatin, and capecitabine as perioperative therapy in microsatellite-stable, resectable colorectal cancer liver metastases: An open-label, single-arm, phase II trial.

讲者：李宇红 | 中山大学肿瘤防治中心

摘要号：3587 | 壁报编号：256

研究名称（英文）：Safety and efficacy evaluation of neoadjuvant chemoradiotherapy plus thymalfasin and tislelizumab for treating MSS/pMMR locally advanced rectal cancer.

讲者：Zhengyang Yang | 首都医科大学附属北京友谊医院

摘要号：3589 | 壁报编号：258

研究名称（英文）：Single-incision laparoscopic surgery vs conventional laparoscopic surgery for colorectal cancer: Short-term outcomes of a multi-center, randomized, controlled trial.

讲者：yaqi zhang | 上海交通大学医学院附属瑞金医院

摘要号：3596 | 壁报编号：265

研究名称（英文）：Performance of a targeted enzymatic methylation-based early detection test by different colorectal cancer subgroups.

讲者：Xiaojian Wu | 中山大学附属第六医院

摘要号：3599 | 壁报编号：268

研究名称（英文）：Neoadjuvant mFOLFOXIRI chemotherapy with or without cadonilimab versus mFOLFOX6 alone in locally advanced colorectal cancer: A randomized phase II study (OPTICAL2).

讲者：Jianwei Zhang | 中山大学附属第六医院

摘要号：3601 | 壁报编号：270

研究名称（英文）：Long-term survival and treatment efficacy in dMMR/MSI-H rectal cancer: A real-world cohort from seven large medical college–affiliated hospitals.

讲者：Siyuan Mi | 中山大学肿瘤防治中心

摘要号：3617 | 壁报编号：286

研究名称（英文）：An early colorectal cancer screening programme based on bisulfite-free sequencing of methylated circulating tumor DNA.

讲者：费儒杉 | 浙江大学医学院附属第一医院

摘要号：TPS3639 | 壁报编号：305a

研究名称（英文）：Stereotactic body radiotherapy combined with PD-1 antibody in unresectable colorectal liver metastases: A prospective, multicenter, single-arm, phase II study (SPARKLE-L).

讲者：Fang He | 中山大学附属第六医院

摘要号：TPS3640 | 壁报编号：305b

研究名称（英文）：Neoadjuvant cetuximab plus tislelizumab combined with chemotherapy in pMMR RAS/BRAF wild-type (wt) locally advanced rectal cancer (LARC): A prospective, multicenter, phase II study.

讲者：Gang Liu | 天津医科大学总医院

摘要号：TPS3641 | 壁报编号：306a

研究名称（英文）：Node-sparing modified short-course radiotherapy combined with CAPOX and tislelizumab versus conventional short-course preoperative chemoradiotherapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer (mRCAT-III): A multicenter, randomized, open-label, phase 3 trial.

讲者：宋章法 | 浙江大学医学院附属邵逸夫医院

摘要号：TPS3645 | 壁报编号：308a

研究名称（英文）：Platform study of circulating tumor DNA–directed adjuvant chemotherapy in colon cancer (CLAUDIA Colon Cancer, KCSG CO22-12).

讲者：Yongjun Cha | 中国医学科学院肿瘤医院

摘要号：TPS3646 | 壁报编号：308b

研究名称（英文）：mFOLFOX6 + bevacizumab + PD-1 monoclonal antibody vs. mFOLFOX6 in locally advanced pMMR/MSS CRC: A multicenter, randomized controlled phase III study (BASKETIII).

讲者：黄俊 | 中山大学附属第六医院

备注：

如有遗漏或任何问题，请给我们留言~

撰写：Babel

排版：Babel

执行：Squid

本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理

来源：医脉通肿瘤科